CN-121971460-A - Application of idarubicin in preparation of medicine for treating benign prostatic hyperplasia

Abstract

The invention discloses an application of idarubicin in preparing a medicament for treating benign prostatic hyperplasia, and relates to the technical field of biological medicines. Use of idarubicin in the manufacture of a medicament for the treatment of benign prostatic hyperplasia. The invention discovers and proves that the idarubicin is applied to BPH treatment for the first time, ① is verified on the specificity and effectiveness of BPH, preferably gland proliferation type BPH, the intervention effect of the idarubicin on a core target TP63 and gland proliferation is clear, ② supports the regulation and control effects of the idarubicin on the prostate volume and gland proliferation through in-vivo experimental data, ③ is subjected to clinical-level curative effect verification, and a clinical application path of subtype screening, drug intervention and curative effect evaluation is established, so that the idarubicin is beneficial to the conversion of the idarubicin in BPH accurate treatment. The research verifies the therapeutic value of idarubicin on BPH, especially gland proliferation type BPH through the complete evidence chain of cell, animal and multicenter clinical retrospective research, and fills the blank in the field.

Inventors

• HAO XIAOWEI
• YANG GUORONG
• LV KAIKAI
• LI RENTANG
• HUA CHENG
• LI YIZHEN
• YANG DONG
• DONG JUAN
• ZHANG XU
• YUAN QING
• Hua Zefeng
• Pang Haigang
• PANG JIAN
• YE CHENXI
• HU QIANG
• WANG YI
• LV CHAO

Assignees

• 中国人民解放军总医院第三医学中心

Dates

Publication Date

20260505

Application Date

20260224

Claims (6)

1. 1. Use of idarubicin in the manufacture of a medicament for the treatment of benign prostatic hyperplasia.
2. 2. The use according to claim 1, wherein the molecular typing of benign prostatic hyperplasia is glandular proliferation.
3. 3. The use according to claim 1, wherein the idarubicin inhibits TP63 expression, prostatic hyperplasia and cell proliferation.
4. 4. A pharmaceutical composition for treating benign prostatic hyperplasia, said pharmaceutical composition comprising: idarubicin.
5. 5. The pharmaceutical composition of claim 4, wherein the molecular typing of benign prostatic hyperplasia is glandular proliferation.
6. 6. The pharmaceutical composition of claim 4, wherein the idarubicin inhibits TP63 expression, prostatic hyperplasia, and cell proliferation.

Description

Application of idarubicin in preparation of medicine for treating benign prostatic hyperplasia Technical Field The invention relates to the technical field of biological medicines, in particular to application of idarubicin in preparation of a medicine for treating benign prostatic hyperplasia. Background Benign Prostatic Hyperplasia (BPH) molecular typing system has been clarified that the gland proliferation type (S-II subtype) is the core subtype with the highest clinical proportion (the queue data shows 60% -65%), and the core pathological characteristics are that the gland proportion is remarkably increased, the growth rate of the transitional area is high, the cell proliferation activity is strong, and the secondary bladder injury is more serious. The subtype patients have progressive aggravation of bladder outlet obstruction and recurrent lower urinary tract symptoms caused by gland continuous hyperproliferation, and have poor long-term response to traditional treatment, so that a targeted therapeutic drug is needed in clinic. The existing first-line medicine (alpha receptor blocker) for treating BPH (for example, gland proliferation type BPH) has obvious limitations that ① alpha reductase inhibitors only can relieve smooth muscle spasm and can not inhibit the core pathological process of gland proliferation, 5 alpha reductase inhibitors can slightly reduce the volume of the prostate, but have slow effect (6-12 months are needed), have limited effect on patients with severe gland proliferation, are difficult to prevent the continuous growth of transitional areas, ② operation treatment (such as transurethral laser enucleation) can cut the proliferation glands, but the proliferation recurrence rate of residual glands after operation reaches 15% -20%, the operation wound can aggravate bladder function injury, ③ clinically lacks a targeting medicine for specifically inhibiting the gland proliferation, the traditional new medicine has long research and development period and high cost, and the medicine for the proliferation target of the BPH has not formed mature products, and can not meet the clinical accurate treatment requirement. Disclosure of Invention In order to solve the technical problems in the prior art, the embodiment of the invention provides application of idarubicin in preparing a medicament for treating benign prostatic hyperplasia. The technical scheme is as follows: use of idarubicin in the manufacture of a medicament for the treatment of benign prostatic hyperplasia. Alternatively, the molecular typing of benign prostatic hyperplasia is glandular proliferation. Optionally, the idarubicin inhibits TP63 expression, prostatic hyperplasia, and cell proliferation. A pharmaceutical composition for treating benign prostatic hyperplasia, the pharmaceutical composition comprising: idarubicin. Alternatively, the molecular typing of benign prostatic hyperplasia is glandular proliferation. Optionally, the idarubicin inhibits TP63 expression, prostatic hyperplasia, and cell proliferation. The technical scheme provided by the embodiment of the invention has the beneficial effects that at least: The invention focuses on BPH, especially on core target TP63 (tumor protein p 63) of gland proliferation type BPH, screens candidate drugs with proliferation inhibition activity, and discovers that the inhibition effect of topoisomerase II inhibitor idarubicin on TP63 expression and cell proliferation in a cell experiment is obviously superior to that of entecavir and cyclopamine waiting drug. The invention discovers and proves that ① verifies the specificity and effectiveness of idarubicin in BPH treatment aiming at BPH, especially gland proliferation type BPH, and clearly shows the intervention effect of the idarubicin on a core target TP63 and gland proliferation, for example, FIG. 1 shows that the idarubicin significantly reduces TP63 protein expression and strongly inhibits cell proliferation (EdU positive cells are significantly reduced by three independent experimental methods of WB, immunofluorescence and CCK-8 in a BPH-1 gland epithelial modelExtremely remarkable), forming a complete evidence chain from target regulation to phenotype change, compared with normal prostate epithelial cells (RWPE-1) and prostate interstitial fibroblasts (WPMY-1), the proliferation inhibition effect of idarubicin in the BPH-1 gland epithelial cells is most remarkable and the downregulation effect of TP63 is most definite, the differentiated pharmacodynamic response prompts that the medicament has a preferential effect on prostate gland source cells and accords with pathological feature positioning of gland proliferation type BPH, meanwhile, the multi-cell line control in figure 1 eliminates the question of generalized cytotoxicity, proves that the inhibition effect of idarubicin in the normal prostate cells is relatively weak rather than showing the same strength toxicity on all cells, supports the selective intervention